Research Topics
| Nancy KemenySummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Management of liver metastases from colorectal cancerNancy Kemeny
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Oncology (Williston Park) 20:1161-76, 1179; discussion 1179-80, 1185-6. 2006..This review considers the timing and sequence of chemotherapy and surgery in this setting, as well as the roles of cryoablation, radiofrequency ablation, and radiation therapy...
The management of resectable and unresectable liver metastases from colorectal cancerNancy Kemeny
Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
Curr Opin Oncol 22:364-73. 2010..To discuss when and who should get liver resection, how to get to resection and what treatments are useful in the pre or postoperative setting...- Implanted hepatic arterial infusion pumpsMargaret K Callahan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
Cancer J 16:142-9. 2010.... - Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)Nancy E Kemeny
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:1395-403. 2006..Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome... - Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinomaNancy E Kemeny
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 27:3465-71. 2009..Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability... - Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancerNancy Kemeny
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:4753-61. 2004..This multicenter study evaluated FU/LV with or without oxaliplatin in patients with metastatic CRC after disease progression on sequential fluoropyrimidine and irinotecan... - Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancerN Kemeny
Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
Ann Oncol 20:1236-41. 2009.... - Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancerNancy Kemeny
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 23:4888-96. 2005..To determine the maximum-tolerated dose (MTD) of concurrent systemic oxaliplatin (Oxal) combinations plus hepatic arterial infusion (HAI) in patients with unresectable hepatic metastases from colorectal cancer... - Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinomaNancy Kemeny
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Surg Oncol 91:97-101. 2005..Based on these data, we performed a phase II trial of hepatic arterial infusion (HAI) of FUDR and Dexamethasone (Dex) plus high-dose Mit-C for patients with unresectable hepatic metastases from colorectal carcinoma... - Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancerNancy E Kemeny
Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
J Clin Oncol 29:884-9. 2011..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)... - Hepatic-arterial chemotherapyN Kemeny
Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10021, USA
Lancet Oncol 2:418-28. 2001..We discuss the phase II and phase III studies of hepatic-arterial infusion therapy, with a focus on liver metastases from colorectal cancer... - Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancerN Kemeny
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 13:1490-6. 2002..Oxaliplatin exerts its antineoplastic activity through the formation of platinum-DNA adducts. Resistance to oxaliplatin is through repair of these adducts, which is inhibited by irinotecan... - Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experiencePatrick S Wolf
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Am Coll Surg 216:41-9. 2013..This study investigates the effect of preoperative chemotherapy for CRCLM on nontumoral liver histology and perioperative outcomes in a contemporary cohort... - Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapyWaldemar F Carlo
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Surg Oncol 87:85-90. 2004..79). CONCLUSIONS: A greater loss of healthy liver following resection of hepatic metastases from colorectal cancer does not seem to predispose to the development of toxicity from adjuvant HAI and systemic chemotherapy... - Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastasesDavid J Gallagher
Department of Medicine, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA
Ann Surg Oncol 16:1844-51. 2009..We investigated the relation between response to neoadjuvant chemotherapy and overall survival (OS) in patients with colorectal liver metastases (CLM)... - Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomesManish A Shah
Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:3296-302. 2005..The clinical evaluation of Drg1 in colorectal cancer has been limited. We performed this study to evaluate the role of Drg1 in a large cohort of patients with metastatic colorectal cancer who were irinotecan naive... - Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control studyMichael D'Angelica
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Ann Surg Oncol 14:759-65. 2007..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection... - Actual 10-year survival after resection of colorectal liver metastases defines cureJames S Tomlinson
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:4575-80. 2007..There is now sufficient follow-up on a significant number of patients to address the curative intent of resecting CLM... - Presurgical chemotherapy in patients being considered for liver resectionNancy Kemeny
Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10021, USA
Oncologist 12:825-39. 2007..The challenge for the future is to develop a multidisciplinary team approach that can design the best treatment plan for patients with liver metastases... - Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastasesPeter J Allen
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Gastrointest Surg 7:109-15; discussion 116-7. 2003.... 
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancerYuman Fong
1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Mol Ther 17:389-94. 2009..During follow-up, no signs of virus reactivation were found. Multimutated HSV can be delivered safely into the human bloodstream to produce selective infection of tumor tissues and biologic effects...- Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancerMithat Gonen
Departments of Epidemiology and Biostatistics, Medicine, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:406-12. 2003.... - Metastatic colorectal cancer: from improved survival to potential cureDavid J Gallagher
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
Oncology 78:237-48. 2010..Better therapies have resulted in prolonged median survival for patients with metastatic disease and a select number of patients can now be cured... - Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancerN Kemeny
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:3303-9. 2003..This regimen seems to have comparable activity to fluorouracil and leucovorin, but further studies are needed to assess whether it improves local control or decreases extrahepatic recurrences... - Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionItaru Endo
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Ann Surg 248:84-96. 2008..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort... - A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignanciesArchie N Tse
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Chemother Pharmacol 64:935-44. 2009..To determine the maximum tolerated dose and duration of hepatic arterial infusion (HAI) gemcitabine in patients with unresectable hepatic metastases from colorectal cancer or primary hepatic malignancies... - Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liverNancy Kemeny
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Hum Gene Ther 17:1214-24. 2006..We conclude that NV1020, a genetically engineered but replication-competent HSV-1 oncolytic virus, can be safely administered into the hepatic artery without significant effects on normal liver function... - Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive casesPeter J Allen
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY10021, USA
J Am Coll Surg 201:57-65. 2005..Longterm durability of pump function was excellent... - Arterial embolization for salvage of hepatic artery infusion pumpsConstantinos T Sofocleous
Division of Interventional Radiology and Image Guided Therapies, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
J Vasc Interv Radiol 17:801-6. 2006..The purpose of this study is to report experience in salvaging HAIPs with arterial embolization... - Treatment of patients with colorectal cancer: emphasis on liver metastasesDavid Gallagher
Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Expert Opin Pharmacother 10:109-24. 2009..In this review, we highlight the developments that have improved survival for patients with colorectal liver metastases and discuss the many issues that challenge further progress... - Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liverKi Young Chung
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Radiat Oncol 15:284-98. 2005..Therefore, the regional approach for hepatobiliary tumors deserves further investigation as well as randomized trials for adequate comparison to new systemic chemotherapies... - KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastasesGarrett M Nash
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Surg Oncol 17:572-8. 2010..To examine more directly whether KRAS mutations are associated with accelerated metastatic progression, we evaluated KRAS mutation as well as Ki-67 expression in patients with colorectal liver metastases not treated with cetuximab... - Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumorsJeremy Kortmansky
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:1875-84. 2005..We designed a phase I clinical trial of FU in combination with UCN-01... - Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancerGary K Schwartz
Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
Anticancer Drugs 15:219-27. 2004..0 mg/m, with manageable toxicity. This combination shows encouraging activity, and survival appears promising in the pre-treated aCRC patient population. Further clinical trials are warranted... - Gemcitabine-related radiation recall preferentially involves internal tissue and organsPhilip A Friedlander
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 100:1793-9. 2004..The development of internal tissue inflammation is reportedly correlated with a shorter interval from the time of completion of radiation therapy to the initiation of chemotherapy... - Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancerN Kemeny
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 19:2687-95. 2001..Although the main objective of this study was to evaluate the toxicity of the combined regimen, a high response rate (74%) was observed... - Molecular therapies for colorectal cancer metastatic to the liverPhilipp Mayer-Kuckuk
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 5:492-500. 2002..Here we review molecular therapies for colorectal cancer metastatic to the liver... - Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancerDavid J Gallagher
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Colorectal Cancer 8:172-4. 2009..This case highlights an important cause of a falsely elevated CEA with abnormal PET imaging... - A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumorsMatthew G Fury
Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
Cancer Chemother Pharmacol 57:671-7. 2006..Vitamin B(12) and folate supplementation may allow for further dose escalation of pralatrexate and probenecid. This is a suitable question for a future study... - Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 16:3858-65. 1998..In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these agents to maximize the potential for synergistic interaction... - Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survivalW R Jarnagin
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 20:1589-95. 2009.... - Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeksS Sharma
Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 7:3963-70. 2001..In conclusion, the recommended Phase II dose for DX-8951f administered as a weekly 24-h infusion on a 3-of-4 week schedule is 0.8 mg/m(2) in minimally pretreated patients and 0.53 mg/m(2) in patients who are heavily pretreated... - A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecanS Sharma
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 11201, USA
Ann Oncol 13:1067-71. 2002..ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras... - Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysisD J Gallagher
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 18:1995-9. 2007..Response rates to systemic chemotherapy are low after tumor progression on oxaliplatin regimens. Hepatic arterial infusion (HAI) therapy in patients with tumor progression is a viable alternative... - Comparative genomic analysis of primary versus metastatic colorectal carcinomasEfsevia Vakiani
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 30:2956-62. 2012..To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites... - Second-line management of metastatic colorectal cancerDavid J Gallagher
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Colorectal Cancer 7:25-32. 2008..This article reviews treatment options after progression on irinotecan- or oxaliplatin-based first-line therapy and highlights some of the difficulties encountered when interpreting data... - Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastasesCelina Ang
Department of Medicine, Gastrointestinal Oncology Service, NY, USA
Breast J 19:96-9. 2013..HAI and systemic chemotherapy is feasible and can benefit selected patients with BCLM, who have progressed on prior therapies. Patients require close monitoring for treatment-limiting toxicities... - Improving response and outcomes for patients with liver-limited metastatic colorectal cancerDavid J Gallagher
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Colorectal Cancer 9:S36-43. 2010..In this article we discuss the biology of colorectal cancer metastases, the rationale for perioperative chemotherapy, and the recent and ongoing investigation of perioperative chemotherapy in the management of CLM... - CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumorsSergey V Shmelkov
Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
J Clin Invest 118:2111-20. 2008.... - Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinomaN Kemeny
Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021
Am J Clin Oncol 11:66-72. 1988..017). As a result, patient accrual continued. Problems encountered with the implementation of the group sequential methodology and the importance of stratification for prognostic variables are discussed... - A phase II trial of streptozotocin and adriamycin in advanced APUD tumorsJ Frame
Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York
Am J Clin Oncol 11:490-5. 1988..With this dose and schedule of administration, STZ and Adriamycin produce modest response rates with objective palliation of disease in patients with advanced amine precursor uptake and decarboxylation (APUD) tumors... - The role of floxuridine in metastatic liver diseaseDerek G Power
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Mol Cancer Ther 8:1015-25. 2009..The high hepatic extraction of FUDR limits systemic side effects. Toxicity includes biliary and gastrointestinal ulcers... - Systemic or regional chemotherapy for liver metastases from colorectal cancer: has the wheel stopped spinning?J R Zalcberg
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Cancer J 10:271-9. 2004.... - Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplificationMarian Iwamoto
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer Biol Ther 3:395-9. 2004..In as much as TS is transcriptionally regulated by E2F-1, these results provide an explanation for the high levels of TS mRNA noted in some tumor samples... - An update on hepatic arterial infusion chemotherapy for colorectal cancerAdam D Cohen
Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Oncologist 8:553-66. 2003..In an attempt to prevent extrahepatic progression, combinations of HAI with systemic chemotherapy, including newer agents such as irinotecan and oxaliplatin, are currently being investigated, with promising early results... - Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
J Clin Oncol 21:2904-11. 2003.... - Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancerSydney Welt
Department of Medicine at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:1347-53. 2003.... - Phase I study of anticolon cancer humanized antibody A33Sydney Welt
Department of Medicine at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:1338-46. 2003..The present study was designed to (a) define the toxicities and maximum tolerated dose of huA33 and (b) determine huA33 immunogenicity... - Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV diseaseGarrett M Nash
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Ann Surg Oncol 9:954-60. 2002..The extent of metastatic disease and the response to chemotherapy are the major determinants of survival. Effective systemic chemotherapy should be given high priority in the treatment of stage IV rectal cancer... - Intrahepatic arterial infusion of chemotherapy: clinical resultsDon S Dizon
Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 29:126-35. 2002..Current research is underway to improve the rate of extrahepatic metastases in patients undergoing HAI... - Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinomaGregory D Leonard
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:2038-48. 2005..This review summarizes the current data on neoadjuvant chemotherapy, the rationale for this approach, potential complications, and future prospects... - Persistent CEA elevation in a patient with psoriasis and a history of metastatic colorectal cancer with no evidence of residual tumorGregory D Leonard
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Dig Dis Sci 49:1652-3. 2004 - Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruptionAlon Scope
Dermatology Service and Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
J Clin Oncol 25:5390-6. 2007..To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy... - Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyLeonard B Saltz
Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:4557-61. 2007..We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer... - Advances in neoadjuvant therapy for colorectal cancer with liver metastasesCarmelo Pozzo
Unit of Medical Oncology, Department of Internal Medicine, Universita Cattolica del Sacro Cuore, Policlinico Universitario A Gemelli, Largo Agostino Gemelli, 8, 00168 Rome, Italy
Cancer Treat Rev 34:293-301. 2008..These trials must include well-defined criteria for resectability and clear reporting of the extent of resection... - Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastasesAnne M Covey
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Surg 247:451-5. 2008.... - Assessing the optimal duration of chemotherapy in patients with colorectal liver metastasesRebekah R White
Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Surg Oncol 97:601-4. 2008..The purpose of this retrospective analysis was to evaluate time to maximal response in patients receiving systemic +/- hepatic arterial infusion (HAI) chemotherapy alone for the treatment of CLM... - Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancerHiromichi Ito
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Ann Surg 247:994-1002. 2008..The objective of this study was to evaluate the impact of postoperative morbidity on the long-term outcome after liver resection for MCRC... - Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastasesGeorge Miller
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Am Coll Surg 205:231-8. 2007..But the benefits of resection and appropriate selection criteria in patients who develop both hepatic and pulmonary metastases are ill defined... - Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two casesGregory D Leonard
Old School of Nursing, Waterford Regional Hospital, Waterford, Ireland
Dis Colon Rectum 49:407-10. 2006..These patients also confirm the importance of continued investigation of fluorouracil modulating agents, which may further enhance the recent progress made with fluorouracil-based combination chemotherapy for colorectal cancer... - Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancerRonan J Kelly
Waterford Regional Hospital, Ardkeen, Waterford, Ireland
Clin Colorectal Cancer 5:166-74. 2005..Continued progress in the field of HAI therapy may reduce the morbidity and mortality associated with CRC, so continued research in this area should be encouraged... - Hepatic arterial infusion after liver resectionNancy E Kemeny
N Engl J Med 352:734-5. 2005 - Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryKi Young Chung
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
J Clin Oncol 23:1803-10. 2005.... - Regional chemotherapy for liver-limited metastatic colorectal cancerDerek G Power
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Colorectal Cancer 7:247-59. 2008..The role of HAI therapy for the treatment of unresectable and resectable disease, as well as the use of other regional strategies such as embolization and ablation, are discussed...
Research Grants
- THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMANancy Kemeny; Fiscal Year: 1993..FUR has a high hepatic extraction; we will test teroxirone extraction. both drugs are effective against colon cancer cell lines (Bertino - I-R01)...
- THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMANancy Kemeny; Fiscal Year: 2001..Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible. ..